Table 1. Definitions of response^*1.

Definition	Monitoring (CP CML, imatinib therapy)
CHR(complete hematological ‧response)	WBC <10 g/l Platelets <450 g/l No granulocyte precursors in differential blood count <5% basophils (all parameters are for peripheral blood) Spleen not palpable	Every 2 weeks until CHR, then every 3 months
Cytogenetic ‧response (bone marrow)	Complete (CCyR): 0% Ph+ Partial (PCyR): 1–35% Ph+ Minor CyR: 36–65% Ph+ Minimal CyR: 66–95% Ph+ No CyR: >95% Ph+	Months 3 and 6, then every 6 months until CCyR achieved and confirmed, then every 12 months*2
Molecular ‧response (qRT-PCR, peripheral blood)	Complete (CMR) not detectable Major (MMR) bcr-abl/control gene ≤0.10	Every 3 months, every 6 months with CCyR + MMR

^*1 Current recommendations for monitoring chronic-phase CML during imatinib therapy; modified according to the recommendations of the European Leukemia Net (ELN) (1, 2, 14–16).

^*2 After confirmed CCyR, cytogenetic monitoring is recommended every 12 months, provided regular molecular monitoring cannot be guaranteed, and should always be carried out in the event of suboptimal response or treatment failure or unexplained anaemia, leukocytopenia and/or thrombocytopenia. Ph, Philadelphia chromosome; G, giga